Simplex Trading
NVLN

Simplex Trading’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Simplex Trading’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100
Closed -$7K – 8268
2019
Q2 		$7K Buy
+100
New +$111 ﹤0.01% 6336
2017
Q3 		– Sell
-103
Closed -$9K – 7059
2017
Q2 		$9K Sell
103
-125
-55% -$1.2K ﹤0.01% 4110
2017
Q1 		$12K Buy
228
+65
+40% +$664 ﹤0.01% 3838
2016
Q4 		$6K Buy
+163
New +$1.44K ﹤0.01% 4269

Other funds holding NVLN

Stonepine Capital Management
Stonepine Capital Management Bend, Oregon $159M AUM 62.27% 1-Year Est. Return
EdgePoint Investment Group
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
Healthcare Value Capital
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return
Franklin Street Advisors
Franklin Street Advisors Chapel Hill, North Carolina $1.82B AUM 22.19% 1-Year Est. Return

Simplex Trading's NVLN Position: Q3 2019 in Review

Simplex Trading sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2019, closing a stake of 10,000 shares — an estimated $7K sold.

Simplex Trading first reported a position in NVLN in Q4 2016 and held it in 5 quarters. The position peaked at $73K in Q1 2017. 31 funds tracked by Wall St. Rank hold NVLN as of Q3 2019.

  • Simplex Trading reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2019 after selling out during the quarter.
  • Simplex Trading sold 10,000 Novelion Therapeutics Inc. Common Shares shares in Q3 2019, an estimated $7K.
  • Simplex Trading first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 5 quarters.
  • Simplex Trading's Novelion Therapeutics Inc. Common Shares position peaked at $73K in Q1 2017.
  • 31 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2019.

Based on Simplex Trading's 13F filing for Q3 2019, filed 15 Oct 2019.